- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06411015
Prognostic Evaluation Prediction Model Survival Spinal Epidural Metastases
Prognostic Evaluation of Prediction Model Survival Spinal Epidural Metastases
Study Overview
Status
Conditions
Detailed Description
The prediction model is web-based and used five parameters: Karnofsky performance score (KPS) (in case of sudden (<24 hours) deterioration the score was used just before the deterioration), the curative intention to treat the primary, the spinal level of the symptomatic tumor, histopathology of the metastasis, and sex. These parameters will be recorded in addition to baseline characteristics. The date of presentation will be recorded. Four months after inclusion of the last patient survival status of all patients will scored. If applicable the date of death will be noted.
Patients are eligible if they suffer from a symptomatic epidural spinal metastatic lesion warranting therapy, either radiation therapy or a combination of surgery and radiation therapy. The nature of the lesion should be verified by pathological examination. In case of an active primary that has recently been diagnosed (less than one year previous to presentation of spinal lesion), the metastatic lesion is considered to be related to this primary. However, if the patient has more than one primary in the history, pathological verification of the tissue is obligatory.
After the patients provided informed consent of using their data for scientific use including the publication of the results, they will be included. The data will be collected, and electronically and anonymized stored. Patients will be included during three successive years. It is estimated that approximately 450 patients can be included. Two centers will participate, Radboud University Medical Center and Haaglanden Medical Center.
Statistical analysis The Cox model will be validated as described earlier 4, first graphically the predictive ability will be plotted, whereas next it will be quantitatively expressed as Harrel's c-index and the Royston -Sauerbrei D-statistic, Rd2. The calibration slope is also calculated. A sample of one third of all patients will be used for validation purpose. If needed the model is adapted. Then the validation is performed using the data of all patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500 HB
- Radboud University Nijmegen Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients with spinal spinal metastasis
- symptomatic
- adult
- informed consent
Exclusion Criteria:
- not understanding informed consent
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
survival after diagnosis of spinal metastasis
Time Frame: minimal 6 months after inclusion
|
survival after diagnosis of spinal metastasis
|
minimal 6 months after inclusion
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Radboudumcnch001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Predictive Cancer Model
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsCompletedSolid Tumor | Predictive Cancer ModelChina
-
Military University Hospital, PragueRecruitingPredictive Cancer ModelCzechia
-
Known Medicine, Inc.M.D. Anderson Cancer Center; Mayo Clinic; Duke Cancer InstituteRecruitingCancer | Effects of Chemotherapy | Predictive Cancer ModelUnited States
-
Air Force Military Medical University, ChinaCompletedColonoscopy | Bowel Preparation | Predictive ModelChina
-
Ningbo No. 1 HospitalCompletedColonoscopy | Predictive Model | External ValidationChina
-
Air Force Military Medical University, ChinaShenzhen Hospital of Southern Medical University; Huaihe Hospital of Henan... and other collaboratorsCompletedColonoscopy | Bowel Preparation | Predictive ModelChina
-
University Hospital, GenevaQIAGEN Gaithersburg, Inc; Hologic, Inc.; Pregnolia ACCompletedLabor Onset | Labor, Induced | Labor, Obstetric | Predictive ModelSwitzerland
-
Chinese PLA General HospitalPeking University First Hospital; Xiangya Hospital of Central South University and other collaboratorsCompleted
-
Beth Israel Deaconess Medical CenterMassachusetts Institute of Technology; TriNetX, LLCActive, not recruitingPancreatic Adenocarcinoma | Predictive Cancer ModelUnited States
-
Fudan UniversityRecruitingMetastasis | Predictive Cancer ModelChina